{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:45:02Z","timestamp":1791233102471,"version":"4.1.0"},"reference-count":97,"publisher":"XMLink","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-1810866"],"award-info":[{"award-number":["NCC-1810866"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["icurology.org"],"crossmark-restriction":false},"short-container-title":["Investig Clin Urol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.4111\/icu.20200602","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T04:31:41Z","timestamp":1622608301000},"page":"361","update-policy":"https:\/\/doi.org\/10.4111\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Emerging treatments for bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer"],"prefix":"10.4111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-275X","authenticated-orcid":false,"given":"Hyung Suk","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University School of Medicine, Goyang, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-1093","authenticated-orcid":false,"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea."},{"name":"Division of Tumor Immunology, Department of Cancer Biomedical Science, Research Institute, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","reference":[{"key":"10.4111\/icu.20200602_ref1","doi-asserted-by":"crossref","first-page":"101802","DOI":"10.1016\/j.canep.2020.101802","volume":"69","author":"Miranda-Filho","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.4111\/icu.20200602_ref2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4143\/crt.2019.138","volume":"51","author":"Jung","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.4111\/icu.20200602_ref3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","volume":"63","author":"Kamat","year":"2013","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.4111\/icu.20200602_ref5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.4111\/icu.20200602_ref8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ijc.20442","volume":"112","author":"Young","year":"2004","journal-title":"Int J Cancer"},{"key":"10.4111\/icu.20200602_ref9","first-page":"2160","volume":"16","author":"Jian","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.4111\/icu.20200602_ref10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/pathogens9121000","volume":"9","author":"Kadir","year":"2020","journal-title":"Pathogens"},{"key":"10.4111\/icu.20200602_ref11","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.vaccine.2019.11.060","volume":"38","author":"Angelidou","year":"2020","journal-title":"Vaccine"},{"key":"10.4111\/icu.20200602_ref12","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref14","doi-asserted-by":"crossref","first-page":"132.e7","DOI":"10.1016\/j.urolonc.2020.07.017","volume":"39","author":"Quhal","year":"2021","journal-title":"Urol Oncol"},{"key":"10.4111\/icu.20200602_ref15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.4111\/icu.20200602_ref16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.urology.2006.03.033","volume":"68","author":"Shariat","year":"2006","journal-title":"Urology"},{"key":"10.4111\/icu.20200602_ref17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.4111\/icu.20200602_ref18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756287215599694","volume":"7","author":"Tang","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.4111\/icu.20200602_ref19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-5347(17)38865-1","volume":"142","author":"Sarosdy","year":"1989","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00345-010-0617-4","volume":"29","author":"Weizer","year":"2011","journal-title":"World J Urol"},{"key":"10.4111\/icu.20200602_ref21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1464-410X.2010.09272.x","volume":"106","author":"Yates","year":"2010","journal-title":"BJU Int"},{"key":"10.4111\/icu.20200602_ref23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref24","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.4111\/icu.20200602_ref25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1756287214541798","volume":"6","author":"Cookson","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.4111\/icu.20200602_ref26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"10.4111\/icu.20200602_ref27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref28","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.4111\/icu.20200602_ref29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.4111\/icu.20200602_ref31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.4111\/icu.20200602_ref32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref33","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"10.4111\/icu.20200602_ref35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-13-332","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Cancer"},{"key":"10.4111\/icu.20200602_ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.4111\/icu.20200602_ref37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref38","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref40","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref42","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bju.12403","volume":"113","author":"Breau","year":"2014","journal-title":"BJU Int"},{"key":"10.4111\/icu.20200602_ref43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","volume":"184","author":"Stimson","year":"2010","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.eururo.2014.12.002","volume":"67","author":"Hounsome","year":"2015","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref45","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"key":"10.4111\/icu.20200602_ref48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref49","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","volume":"192","author":"McKiernan","year":"2014","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/tau.2018.09.09","volume":"8","author":"Hendricksen","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.4111\/icu.20200602_ref52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref53","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jps.2600780502","volume":"78","author":"Chien","year":"1989","journal-title":"J Pharm Sci"},{"key":"10.4111\/icu.20200602_ref55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.4111\/icu.20200602_ref56","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.4111\/icu.20200602_ref57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(01)63021-0","volume":"160","author":"Nseyo","year":"1998","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref58","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","volume":"31","author":"Bader","year":"2013","journal-title":"Urol Oncol"},{"key":"10.4111\/icu.20200602_ref59","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euf.2018.08.005","volume":"4","author":"Railkar","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.4111\/icu.20200602_ref61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ucl.2019.09.012","volume":"47","author":"Sathianathen","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.4111\/icu.20200602_ref62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"key":"10.4111\/icu.20200602_ref63","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.4111\/icu.20200602_ref64","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7 Suppl","key":"10.4111\/icu.20200602_ref65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.4111\/icu.20200602_ref66","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"key":"10.4111\/icu.20200602_ref68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"Song","year":"2019","journal-title":"EBioMedicine"},{"key":"10.4111\/icu.20200602_ref69","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"10.4111\/icu.20200602_ref70","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.4111\/icu.20200602_ref72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref73","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.4111\/icu.20200602_ref74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2020.38.6_suppl.442","volume":"38","author":"Boorjian","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.4111\/icu.20200602_ref76","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref77","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"issue":"4 Suppl","key":"10.4111\/icu.20200602_ref78","first-page":"e72","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"key":"10.4111\/icu.20200602_ref79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.4111\/icu.20200602_ref80","doi-asserted-by":"crossref","first-page":"575258","DOI":"10.3389\/fimmu.2020.575258","volume":"11","author":"Kacew","year":"2020","journal-title":"Front Immunol"},{"issue":"6 Suppl","key":"10.4111\/icu.20200602_ref81","doi-asserted-by":"crossref","first-page":"TPS603","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS603","volume":"38","author":"Steinberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.4111\/icu.20200602_ref82","unstructured":"US National Library of Medicine. A phase 1 dose-escalation study of intravesical MK-3475 and bacillus Calmette-Guerin (BCG) in subjects with high risk and BCG-refractory non-muscle-invasive bladder cancer [Internet]. Bethesda (MD). US National Library of Medicine. 2016. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808143"},{"key":"10.4111\/icu.20200602_ref83","unstructured":"US National Library of Medicine. A phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG) [Internet]. Bethesda (MD). US National Library of Medicine. 2020. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04387461"},{"key":"10.4111\/icu.20200602_ref84","unstructured":"US National Library of Medicine. A phase I single-arm study of the combination of durvalumab (MEDI4736) and vicinium (oportuzumab monatox, VB4-845) in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus Calmette-Guerin (BCG) [Internet]. Bethesda (MD). US National Library of Medicine. 2017. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03258593"},{"key":"10.4111\/icu.20200602_ref85","unstructured":"US National Library of Medicine. Phase 1\/2 study of modern immunotherapy in BCG-relapsing urothelial carcinoma of the bladder - (ADAPT-BLADDER) HCRN GU16-243 [Internet]. Bethesda (MD). US National Library of Medicine. 2017. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03317158"},{"key":"10.4111\/icu.20200602_ref86","unstructured":"US National Library of Medicine. Intravesical administration of durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative [Internet]. Bethesda (MD). US National Library of Medicine. 2018. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759496."},{"key":"10.4111\/icu.20200602_ref87","unstructured":"US National Library of Medicine. Bladder preservation by radiotherapy and immunotherapy in BCG unresponsive non-muscle invasive bladder cancer (PREVERT) [Internet]. Bethesda (MD). US National Library of Medicine. 2019. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03950362"},{"key":"10.4111\/icu.20200602_ref88","unstructured":"US National Library of Medicine. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer [Internet]. Bethesda (MD). US National Library of Medicine. 2016. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02844816"},{"key":"10.4111\/icu.20200602_ref89","unstructured":"US National Library of Medicine. A phase 2, randomized, open-label study of nivolumab or nivolumab\/BMS-986205 alone or combined with intravesical BCG in participants With BCG-unresponsive, high-risk, non-muscle invasive bladder cancer [Internet]. Bethesda (MD). US National Library of Medicine. 2018. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03519256"},{"key":"10.4111\/icu.20200602_ref90","unstructured":"US National Library of Medicine. A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory non-muscle invasive urothelial carcinoma of the bladder cancer [Internet]. Bethesda (MD). US National Library of Medicine. 2014. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02202772"},{"key":"10.4111\/icu.20200602_ref91","unstructured":"US National Library of Medicine. A phase II clinical study of intravesical photodynamic therapy in patients with BCG-unresponsive non-muscle invasive bladder cancer (\u201cNMIBC\u201d) or patients who are intolerant to BCG therapy (\u201cStudy\u201d). [Internet]. Bethesda (MD). US National Library of Medicine. 2019. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03945162"},{"key":"10.4111\/icu.20200602_ref92","unstructured":"US National Library of Medicine. Phase I\/II trial of bacillus Calmette-Gu\u00e9rin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade non-muscle invasive bladder cancer [Internet]. Bethesda (MD). US National Library of Medicine. 2019. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179162"},{"key":"10.4111\/icu.20200602_ref93","unstructured":"US National Library of Medicine. Intravesical phase 1\/1b study of STING agonist E7766 in NMIBC including subjects unresponsive to BCG therapy, INPUT-102 [Internet]. Bethesda (MD). US National Library of Medicine. 2019. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04109092"},{"key":"10.4111\/icu.20200602_ref94","unstructured":"US National Library of Medicine. A phase I\/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy [Internet]. Bethesda (MD). US National Library of Medicine. 2015. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02371447"},{"key":"10.4111\/icu.20200602_ref95","unstructured":"US National Library of Medicine. A phase 3 study of CG0070 in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus-Calmette-Guerin (BCG) [Internet]. Bethesda (MD). US National Library of Medicine. 2020. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04452591"},{"key":"10.4111\/icu.20200602_ref96","unstructured":"US National Library of Medicine. A phase 3, randomized, comparator-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is either persistent or recurrent following BCG induction or that is na\u00efve to BCG treatment (KEYNOTE-676) [Internet]. Bethesda (MD). US National Library of Medicine. 2018. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711032"},{"key":"10.4111\/icu.20200602_ref97","unstructured":"US National Library of Medicine. A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent after treatment with BCG [Internet]. Bethesda (MD). US National Library of Medicine. 2019. cited 2020 Oct 31. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04149574"}],"container-title":["Investigative and Clinical Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/icurology.org\/pdf\/10.4111\/icu.20200602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.20200602","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.20200602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:49:24Z","timestamp":1624942164000},"score":1,"resource":{"primary":{"URL":"https:\/\/icurology.org\/DOIx.php?id=10.4111\/icu.20200602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4111\/icu.20200602","relation":{},"ISSN":["2466-0493","2466-054X"],"issn-type":[{"value":"2466-0493","type":"print"},{"value":"2466-054X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"2020-12-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-27","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 The Korean Urological Association, 2021","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}